What is the current Ustekinumab Biosimilars market size?

The Ustekinumab Biosimilars market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Ustekinumab Biosimilars market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Ustekinumab Biosimilars market?

Key drivers include rising prevalence of chronic diseases and growing adoption of biosimilars worldwide.

What are the challenges facing the Ustekinumab Biosimilars market?

Challenges include high development costs, stringent regulatory requirements, and intense market competition.

Which regions are leading the Ustekinumab Biosimilars market?

North America and Europe are leading the market, driven by strong healthcare infrastructure.

Who are the top companies in the Ustekinumab Biosimilars market?

Top companies include Johnson & Johnson, Novartis, and Pfizer, with a strong pipeline of biosimilars.

What future opportunities exist in the Ustekinumab Biosimilars market?

Future opportunities include emerging markets, increasing use of biosimilars, and advancements in technology.

How will technology impact the Ustekinumab Biosimilars market?

Technology will improve manufacturing processes, enhance product quality, and increase accessibility of biosimilars globally.

What is the current regulatory landscape for Ustekinumab Biosimilars?

The regulatory landscape is evolving, with increasing approvals from FDA and EMA, and growing adoption of biosimilars worldwide.

What is the future outlook for the Ustekinumab Biosimilars market?

The future outlook is positive, with increasing demand, growing adoption, and rising market size expected in the coming years.

Ustekinumab Biosimilars Market Growth Drivers & Forecast 2033

Ustekinumab Biosimilars by Application (Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis, Psoriatic Arthritis, Other), by Types (Subcutaneous Injection, Intravenous Infusion), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Ustekinumab Biosimilars Market Overview

The Ustekinumab Biosimilars market refers to the global market for biosimilar versions of Ustekinumab, a monoclonal antibody used to treat various autoimmune diseases. As the Ustekinumab Biosimilars market size is expected to witness significant growth, driven by increasing demand for cost-effective treatments, the growth outlook and market forecast are crucial for industry players. The Ustekinumab Biosimilars market is poised for industry expansion, with the global market estimated to be around $1.4 billion in 2025. The market is expected to grow at a CAGR of 24.1% from 2026 to 2033, driven by macro drivers such as increasing prevalence of autoimmune diseases and rising healthcare costs.

Loading chart…

Key forces shaping the Ustekinumab Biosimilars industry include technology shifts towards more efficient manufacturing processes, regulations supporting the development of biosimilars, and competitive intensity driven by the entry of new players. The largest region for Ustekinumab Biosimilars is expected to be North America, while the fastest-growing region is anticipated to be Asia-Pacific. As the market continues to evolve, industry players must stay informed about the latest developments and trends to remain competitive.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teva Pharmaceutical Industries Ltd.; Amgen Inc.; Samsung Bioepis Co., Ltd.; Sandoz International GmbH; Biocon Biologics Limited; Celltrion Inc.; Qyuns Therapeutics; Bio-Thera Solutions, Ltd.; Huadong Medicine Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Ustekinumab Biosimilars market is poised for significant growth, driven by increasing demand for affordable treatment options for chronic diseases such as psoriasis and Crohn's disease. The Ustekinumab Biosimilars market size is expected to expand rapidly, with a promising growth forecast that underscores the potential for biosimilars to disrupt traditional biologic markets.

Growth Drivers2 items

Rising prevalence of chronic inflammatory diseases, such as psoriasis and Crohn's disease, is fueling demand for effective and affordable treatment options, including Ustekinumab Biosimilars.

Government initiatives and regulatory support for the development and approval of biosimilars are expected to drive the Ustekinumab Biosimilars market size and growth forecast.

Restraints2 items

High development costs and complex manufacturing processes for biosimilars may hinder the growth of the Ustekinumab Biosimilars market and impact the growth forecast.

Stringent regulatory requirements and patent protection for originator biologics may limit the availability of Ustekinumab Biosimilars and restrict market growth.

Opportunities2 items

Emerging markets in Asia and Latin America offer significant opportunities for Ustekinumab Biosimilars manufacturers to expand their presence and drive growth in the Ustekinumab Biosimilars market.

Increasing adoption of biosimilars in Europe and the United States is expected to drive the Ustekinumab Biosimilars market size and growth forecast.

Challenges2 items

Ensuring the quality and efficacy of Ustekinumab Biosimilars is a significant challenge, as it requires complex testing and validation procedures to demonstrate biosimilarity to the reference product.

Managing the supply chain and pricing strategies for Ustekinumab Biosimilars will be crucial to achieving commercial success and driving growth in the Ustekinumab Biosimilars market.

Market Segmentation

Loading chart…

The Ustekinumab Biosimilars market can be segmented based on Application, which refers to the therapeutic areas where Ustekinumab Biosimilars are used. This segmentation contributes to the overall market size by highlighting the specific disease areas where these biosimilars are most effective. The main applications of Ustekinumab Biosimilars include Crohn's disease, ulcerative colitis, and psoriasis. Understanding these applications is crucial for Ustekinumab Biosimilars segmentation as it helps in identifying the target patient population and developing effective treatment strategies.

Another significant segmentation category for the Ustekinumab Biosimilars market is Types, which includes subtypes such as [object Object] and [object Object]. These subtypes differ in terms of their molecular structure, production process, and pharmacokinetic properties. Analyzing these types and subtypes is essential for understanding the market taxonomy of Ustekinumab Biosimilars, as it enables the identification of opportunities for innovation and differentiation in the market. By examining the various types and subtypes, manufacturers can develop biosimilars with improved efficacy, safety, and cost-effectiveness.

Ustekinumab Biosimilars Segmentation Breakdown9 items

Application

Crohn's Disease

Ulcerative Colitis

Plaque Psoriasis

Psoriatic Arthritis

Other

Types

Subcutaneous Injection

Intravenous Infusion

Regional Insights

Loading chart…

The Ustekinumab Biosimilars market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of biosimilars, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, demographics and ecosystem maturity; for Europe, policies and infrastructure; for Asia Pacific, investments and adoption; for Latin America, infrastructure and demographics; and for Middle East & Africa, policies and ecosystem maturity. These factors will contribute to the regional forecast and shape the Ustekinumab Biosimilars market.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by the increasing adoption of biosimilars and significant investments in healthcare infrastructure. In contrast, Middle East & Africa are expected to have a relatively lower market share due to limited infrastructure and ecosystem maturity.

Competitive Landscape

The Ustekinumab Biosimilars market is moderately consolidated, driven by a mix of global players and local companies. The Ustekinumab Biosimilars competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on expanding their product portfolios and strengthening their distribution networks, while local companies are concentrating on regional expansion and localization.

Companies in the Ustekinumab Biosimilars market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies need to focus on technology, service model, channel strength, customization, and cost advantages. The following companies are pursuing different strategic focuses:

Teva Pharmaceutical Industries Ltd. - regional expansion

Amgen Inc. - innovation pipeline

Samsung Bioepis Co., Ltd. - local manufacturing

Sandoz International GmbH - OEM tie-ups

Biocon Biologics Limited - vertical integration

Celltrion Inc. - premium pricing

Key Ustekinumab Biosimilars Companies9 items

Teva Pharmaceutical Industries Ltd.

Amgen Inc.

Samsung Bioepis Co., Ltd.

Sandoz International GmbH

Biocon Biologics Limited

Celltrion Inc.

Qyuns Therapeutics

Bio-Thera Solutions, Ltd.

Huadong Medicine Co., Ltd.

Market Ecosystem

The Ustekinumab Biosimilars ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream channels and end users. This ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where integrators and manufacturers produce the biosimilars; and downstream, where distributors, channels, and service providers deliver the final products to end users. Understanding the Ustekinumab Biosimilars ecosystem through a value chain analysis is crucial for identifying how value is created and captured across different stages.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce biosimilar products

Technology providers — offer manufacturing and development technologies

Distributors / channel partners — deliver products to healthcare providers

Service providers / after-sales — provide support and maintenance services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — establish and enforce biosimilar approval standards

The flow of value in the Ustekinumab Biosimilars ecosystem is influenced by various control points, including regulatory approvals and standards set by regulatory bodies. Dependency risks, such as input constraints and approval timelines, can impact the ecosystem's efficiency. Furthermore, switching costs, partnerships, and interoperability requirements can affect how participants interact and collaborate. The ecosystem's structure and dynamics can differ by region due to varying regulatory environments, market conditions, and healthcare systems, leading to distinct challenges and opportunities for participants in the Ustekinumab Biosimilars ecosystem.

Recent Industry Insights

The Ustekinumab Biosimilars industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships and collaborations have been formed to enhance the production and distribution of Ustekinumab Biosimilars. Furthermore, there have been several mergers & acquisitions that have reshaped the competitive landscape of the industry. Recent product/technology launches have also expanded the treatment options for patients, driving growth in the market.

Additionally, regulatory changes have played a crucial role in shaping the Ustekinumab Biosimilars industry. A shift in consumer or enterprise trends has led to increased demand for affordable and effective treatments, driving the adoption of Ustekinumab Biosimilars. The industry has also seen significant funding rounds or expansions, enabling companies to invest in research and development, and enhance their manufacturing capabilities.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Ustekinumab Biosimilars market outlook. The market attractiveness is moderate, driven by increasing demand for affordable treatment options and a growing patient pool. The competitive intensity is high, with multiple players vying for market share. The long-term outlook is positive, with expected growth driven by expanding indications and rising adoption in emerging markets.

The innovation landscape is evolving, with ongoing research focused on improving efficacy and reducing costs. The demand-supply balance is expected to be stable, with biosimilar manufacturers increasing production to meet growing demand. However, key risk factors include regulatory challenges, patent disputes, and intense competition, which may impact market growth. Overall, the Ustekinumab Biosimilars market presents opportunities for growth, but requires careful navigation of the competitive and regulatory landscape.

11 items

1. Executive Summary

2. Ustekinumab Biosimilars Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Ustekinumab Biosimilars Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Ustekinumab Biosimilars Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Crohn's Disease

6.1.2. Ulcerative Colitis

6.1.3. Plaque Psoriasis

6.1.4. Psoriatic Arthritis

6.1.5. Other

6.2. Global Ustekinumab Biosimilars Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Subcutaneous Injection

6.2.2. Intravenous Infusion

6.3. Global Ustekinumab Biosimilars Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Ustekinumab Biosimilars Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Ustekinumab Biosimilars Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Ustekinumab Biosimilars Market Competition by Key Manufacturers

8.1. Global Ustekinumab Biosimilars Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Ustekinumab Biosimilars: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Teva Pharmaceutical Industries Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Amgen Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Samsung Bioepis Co., Ltd.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sandoz International GmbH

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Biocon Biologics Limited

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Celltrion Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Qyuns Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bio-Thera Solutions, Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Huadong Medicine Co., Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Ustekinumab Biosimilars Market

Figure 4: Global Ustekinumab Biosimilars Market: Drivers

Figure 5: Global Ustekinumab Biosimilars Market: Challenges

Figure 6: Global Ustekinumab Biosimilars Market: Trends

Figure 7: Global Ustekinumab Biosimilars Market: Opportunity

Figure 8: Global Ustekinumab Biosimilars Market: Restraint

Figure 9: Global Ustekinumab Biosimilars Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Ustekinumab Biosimilars Market Value (USD Million) By Region

Figure 15: Global Ustekinumab Biosimilars Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Ustekinumab Biosimilars Market Value (USD Million) By Region

Figure 23: Global Ustekinumab Biosimilars Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Ustekinumab Biosimilars Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Ustekinumab Biosimilars Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Ustekinumab Biosimilars Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Ustekinumab Biosimilars Market Value (USD Million) By Region

Table 10: Global Ustekinumab Biosimilars Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Ustekinumab Biosimilars Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Ustekinumab Biosimilars Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Ustekinumab Biosimilars Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 31: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 32: Amgen Inc. Basic Information And Sales Area

Table 33: Amgen Inc.. Products Portfolio

Table 34: Samsung Bioepis Co., Ltd. Basic Information And Sales Area

Table 35: Samsung Bioepis Co., Ltd.. Products Portfolio

Table 36: Sandoz International GmbH Basic Information And Sales Area

Table 37: Sandoz International GmbH. Products Portfolio

Table 38: Biocon Biologics Limited Basic Information And Sales Area

Table 39: Biocon Biologics Limited. Products Portfolio

Table 40: Celltrion Inc. Basic Information And Sales Area

Table 41: Celltrion Inc.. Products Portfolio

Table 42: Qyuns Therapeutics Basic Information And Sales Area

Table 43: Qyuns Therapeutics. Products Portfolio

Table 44: Bio-Thera Solutions, Ltd. Basic Information And Sales Area

Table 45: Bio-Thera Solutions, Ltd.. Products Portfolio

Table 46: Huadong Medicine Co., Ltd. Basic Information And Sales Area

Table 47: Huadong Medicine Co., Ltd.. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Ustekinumab Biosimilars Market Value (USD Million) By Region

Table 53: Global Ustekinumab Biosimilars Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Ustekinumab Biosimilars Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teva Pharmaceutical Industries Ltd.; Amgen Inc.; Samsung Bioepis Co., Ltd.; Sandoz International GmbH; Biocon Biologics Limited; Celltrion Inc.; Qyuns Therapeutics; Bio-Thera Solutions, Ltd.; Huadong Medicine Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of chronic inflammatory diseases, such as psoriasis and Crohn's disease, is fueling demand for effective and affordable treatment options, including Ustekinumab Biosimilars.

Government initiatives and regulatory support for the development and approval of biosimilars are expected to drive the Ustekinumab Biosimilars market size and growth forecast.

Restraints2 items

High development costs and complex manufacturing processes for biosimilars may hinder the growth of the Ustekinumab Biosimilars market and impact the growth forecast.

Stringent regulatory requirements and patent protection for originator biologics may limit the availability of Ustekinumab Biosimilars and restrict market growth.

Opportunities2 items

Increasing adoption of biosimilars in Europe and the United States is expected to drive the Ustekinumab Biosimilars market size and growth forecast.

Challenges2 items

Managing the supply chain and pricing strategies for Ustekinumab Biosimilars will be crucial to achieving commercial success and driving growth in the Ustekinumab Biosimilars market.

Market Segmentation

Loading chart…

Ustekinumab Biosimilars Segmentation Breakdown9 items

Application

Crohn's Disease

Ulcerative Colitis

Plaque Psoriasis

Psoriatic Arthritis

Other

Types

Subcutaneous Injection

Intravenous Infusion

Regional Insights

Loading chart…

Competitive Landscape

Teva Pharmaceutical Industries Ltd. - regional expansion

Amgen Inc. - innovation pipeline

Samsung Bioepis Co., Ltd. - local manufacturing

Sandoz International GmbH - OEM tie-ups

Biocon Biologics Limited - vertical integration

Celltrion Inc. - premium pricing

Key Ustekinumab Biosimilars Companies9 items

Teva Pharmaceutical Industries Ltd.

Amgen Inc.

Samsung Bioepis Co., Ltd.

Sandoz International GmbH

Biocon Biologics Limited

Celltrion Inc.

Qyuns Therapeutics

Bio-Thera Solutions, Ltd.

Huadong Medicine Co., Ltd.

Market Ecosystem

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce biosimilar products

Technology providers — offer manufacturing and development technologies

Distributors / channel partners — deliver products to healthcare providers

Service providers / after-sales — provide support and maintenance services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — establish and enforce biosimilar approval standards

Recent Industry Insights

Analyst Overview

Table of Contents